Overview

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Status:
Not yet recruiting
Trial end date:
2026-02-07
Target enrollment:
Participant gender:
Summary
This is an multicenter, open-label, dose-escalation study of the study drug YH004 . The study is designed to determine the safety, tolerability, maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of YH004 in subjects with advanced solid tumors and relapsed or refractory Non-Hodgkin lymphoma.
Phase:
Phase 1
Details
Lead Sponsor:
Eucure (Beijing) Biopharma Co., Ltd